Published :
Tables : 51
Figures : 45
Category : Healthcare
No. of Pages : 230
Report Code : HC-U5109
Gaucher Disease Treatment Market is poised to value over USD 2.4 billion during the forecast period 2022 to 2028. Gaucher disease is an inherited, rare condition. The condition pertains to lipid metabolism. There is not enough of an enzyme called glucocerebrosidase if you have it. The result is that too much fatty substance builds up in the spleen, liver, lungs, bones, and even the brain. As a consequence, these organs are unable to function normally. After starting treatment with enzyme replacement therapy, miglustat (Zavesca), elglustat (Cerdelga), and osteoporosis drugs, many people suffering from Gaucher disease have seen improvements in their symptoms. The doctor might recommend a bone marrow transplant or splenectomy if your symptoms are too severe for less invasive treatments. In recent years, the US Food and Drug Administration (FDA) has authorised a number of medications for illness treatment. Vpriv (velaglucerase alfa) was licenced by the FDA in 2010 as an enzyme replacement therapy (ERT) for type 1 Gaucher disease. Elelyso (taliglucerase alfa) and Cerdelga (eliglustat) were authorised by the FDA in 2012 and 2014, respectively, for type 1 Gaucher disease. These medications provide a choice of solutions based on individual needs, which is projected to drive market expansion. The European Therapies Agency (EMA) and the US Food and Drug Administration (FDA) cooperated in July 2017 to encourage the adoption of novel techniques in the development of Gaucher disease medicines. It is the most prevalent lysosomal storage disease, with a prevalence of 1 in every 50,000 live births. The perinatal fatal type of the illness is the most severe. Gaucher illness is thought to present itself most strongly in the Jewish community of Eastern and Central Europe, affecting 1 out of every 450 persons and 1 out of every 10 disease carriers within the descend. Increased medical progress in rare condition research and development is raising awareness and may eventually lead to a cure. FutureWise Market Research has instantiated a report that provides an intricate analysis of Gaucher Disease Treatment Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market. According to the research study conducted by FutureWise research analysts, the Gaucher Disease Treatment Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical. Major players included in the Gaucher Disease Treatment Market: • Abbott • Aptalis Pharma • Genzyme Corporation • GlaxoSmithKline (GSK) • Pfizer Inc. • Shire Human Genetic Therapies, Inc. • Eli Lilly and Company • Enobia Pharma Inc. • Anthera Pharmaceuticals, Inc. • BioMarin Pharmaceutical Inc. • MedPro Rx • Zymenex A/S • Merck Serono (Note: The list of the major players will be updated with the latest market scenario and trends) Gaucher Disease Treatment Market Segmentation: By Disease Type • Type 1 (Neuropathic Forms) • Type 2 (Perinatal Lethal Form) • Type 3 (Slow-Neurologic Decay Form) By Medication • Enzyme replacement therapy (ERT) o Imiglucerase (Cerezyme) o Velaglucerase alfa (VPRIV) o Taliglucerase alfa (Elelyso) o Others • Substrate reduction therapy (SRT) o Glucosylceramide synthase inhibitors o Miglustat o Eliglustat • Surgical o Bone marrow transplant o Spleen Removal By End User • Hospitals • Ambulatory Surgical Centers • Clinical research institutes By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa Gaucher Disease Treatment Market Sample Video: Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key trends • Key data-points affecting market growth Objectives of the Study: • To provide with an exhaustive analysis on the Gaucher Disease Treatment Market By Disease Type, By Medication, By End User and By Region. • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa. • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
Gaucher disease is an inherited, rare condition. The condition pertains to lipid metabolism. There is not enough of an enzyme called glucocerebrosidase if you have it. The result is that too much fatty substance builds up in the spleen, liver, lungs, bones, and even the brain. As a consequence, these organs are unable to function normally.
After starting treatment with enzyme replacement therapy, miglustat (Zavesca), elglustat (Cerdelga), and osteoporosis drugs, many people suffering from Gaucher disease have seen improvements in their symptoms. The doctor might recommend a bone marrow transplant or splenectomy if your symptoms are too severe for less invasive treatments.
In recent years, the US Food and Drug Administration (FDA) has authorised a number of medications for illness treatment. Vpriv (velaglucerase alfa) was licenced by the FDA in 2010 as an enzyme replacement therapy (ERT) for type 1 Gaucher disease. Elelyso (taliglucerase alfa) and Cerdelga (eliglustat) were authorised by the FDA in 2012 and 2014, respectively, for type 1 Gaucher disease. These medications provide a choice of solutions based on individual needs, which is projected to drive market expansion.
The European Therapies Agency (EMA) and the US Food and Drug Administration (FDA) cooperated in July 2017 to encourage the adoption of novel techniques in the development of Gaucher disease medicines.
It is the most prevalent lysosomal storage disease, with a prevalence of 1 in every 50,000 live births. The perinatal fatal type of the illness is the most severe. Gaucher illness is thought to present itself most strongly in the Jewish community of Eastern and Central Europe, affecting 1 out of every 450 persons and 1 out of every 10 disease carriers within the descend. Increased medical progress in rare condition research and development is raising awareness and may eventually lead to a cure.
FutureWise Market Research has instantiated a report that provides an intricate analysis of Gaucher Disease Treatment Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.
According to the research study conducted by FutureWise research analysts, the Gaucher Disease Treatment Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.
Major players included in the Gaucher Disease Treatment Market: • Abbott • Aptalis Pharma • Genzyme Corporation • GlaxoSmithKline (GSK) • Pfizer Inc. • Shire Human Genetic Therapies, Inc. • Eli Lilly and Company • Enobia Pharma Inc. • Anthera Pharmaceuticals, Inc. • BioMarin Pharmaceutical Inc. • MedPro Rx • Zymenex A/S • Merck Serono (Note: The list of the major players will be updated with the latest market scenario and trends)
Gaucher Disease Treatment Market Segmentation: By Disease Type • Type 1 (Neuropathic Forms) • Type 2 (Perinatal Lethal Form) • Type 3 (Slow-Neurologic Decay Form)
By Medication • Enzyme replacement therapy (ERT) o Imiglucerase (Cerezyme) o Velaglucerase alfa (VPRIV) o Taliglucerase alfa (Elelyso) o Others • Substrate reduction therapy (SRT) o Glucosylceramide synthase inhibitors o Miglustat o Eliglustat • Surgical o Bone marrow transplant o Spleen Removal
By End User • Hospitals • Ambulatory Surgical Centers • Clinical research institutes
By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa
Gaucher Disease Treatment Market Sample Video:
Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants
FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key trends • Key data-points affecting market growth
Objectives of the Study: • To provide with an exhaustive analysis on the Gaucher Disease Treatment Market By Disease Type, By Medication, By End User and By Region. • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa. • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions
Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders 2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study 3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights 4. Gaucher Disease Treatment Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Gaucher Disease Treatment Market Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Gaucher Disease Treatment Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Gaucher Disease Treatment Market, By Disease Type Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Type 1 (Neuropathic Forms) 7.2. Type 2 (Perinatal Lethal Form) 7.3. Type 3 (Slow-Neurologic Decay Form) 8. Gaucher Disease Treatment Market, By Medication Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Enzyme replacement therapy (ERT) 8.1.1. Imiglucerase (Cerezyme) 8.1.2. Velaglucerase alfa (VPRIV) 8.1.3. Taliglucerase alfa (Elelyso) 8.1.4. Others 8.2. Substrate reduction therapy (SRT) 8.2.1. Glucosylceramide synthase inhibitors 8.2.1.1. Miglustat 8.2.1.2. Eliglustat 8.3. Surgical 8.3.1. Bone marrow transplant 8.3.2. Spleen Removal 9. Gaucher Disease Treatment Market, By End User Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. Hospitals 9.2. Ambulatory Surgical Centers 9.3. Clinical research institutes 10. North America Gaucher Disease Treatment Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 10.1. Introduction 10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 10.2.1. U.S.A 10.2.2. Canada 10.2.3. Mexico 10.3. Market Size (USD Million) Forecast for North America 2022-2028 11. Latin America Gaucher Disease Treatment Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 11.2.1. Brazil 11.2.2. Venezuela 11.2.3. Argentina 11.2.4. Rest of Latin America 11.3. Market Size (USD Million) Forecast for Latin America 2022-2028 12. Europe Gaucher Disease Treatment Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. Germany 12.2.2. U.K 12.2.3. France 12.2.4. Italy 12.2.5. Spain 12.2.6. Russia 12.2.7. Poland 12.2.8. Rest of Europe 12.3. Market Size (USD Million) Forecast for Europe 2022-2028 13. Asia Pacific Gaucher Disease Treatment Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. Japan 13.2.2. China 13.2.3. India 13.2.4. Australia and New Zealand 13.2.5. ASEAN 13.2.6. Rest of Asia Pacific 13.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028 14. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 14.2.1. GCC 14.2.2. Israel 14.2.3. South Africa 14.2.4. Rest of MEA 14.3. Market Size (USD Million) Forecast for MEA 2022-2028 15. Market Share Analysis and Competitive Landscape 15.1. Global Landscape - Key Players, Revenue and Presence 15.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 15.3. Global Emerging Companies 15.4. North America - Market Share Analysis and Key Regional Players 15.5. Europe - Market Share Analysis and Key Regional Players 15.6. Asia Pacific - Market Share Analysis and Key Regional Players 15.7. Global Key Player - Growth Matrix 16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts) 16.1. Abbott 16.1.1. Company Overview 16.1.2. Product Portfolio 16.1.3. SWOT Analysis 16.1.4. Financial Overview 16.1.5. Strategic Overview 16.2. Aptalis Pharma 16.2.1. Company Overview 16.2.2. Product Portfolio 16.2.3. SWOT Analysis 16.2.4. Financial Overview 16.2.5. Strategic Overview 16.3. Genzyme Corporation 16.3.1. Company Overview 16.3.2. Product Portfolio 16.3.3. SWOT Analysis 16.3.4. Financial Overview 16.3.5. Strategic Overview 16.4. GlaxoSmithKline (GSK) 16.4.1. Company Overview 16.4.2. Product Portfolio 16.4.3. SWOT Analysis 16.4.4. Financial Overview 16.4.5. Strategic Overview 16.5. Pfizer Inc. 16.5.1. Company Overview 16.5.2. Product Portfolio 16.5.3. SWOT Analysis 16.5.4. Financial Overview 16.5.5. Strategic Overview 16.6. Shire Human Genetic Therapies, Inc. 16.6.1. Company Overview 16.6.2. Product Portfolio 16.6.3. SWOT Analysis 16.6.4. Financial Overview 16.6.5. Strategic Overview 16.7. Eli Lilly and Company 16.7.1. Company Overview 16.7.2. Product Portfolio 16.7.3. SWOT Analysis 16.7.4. Financial Overview 16.7.5. Strategic Overview 16.8. Enobia Pharma Inc. 16.8.1. Company Overview 16.8.2. Product Portfolio 16.8.3. SWOT Analysis 16.8.4. Financial Overview 16.8.5. Strategic Overview 16.9. Anthera Pharmaceuticals, Inc. 16.9.1. Company Overview 16.9.2. Product Portfolio 16.9.3. SWOT Analysis 16.9.4. Financial Overview 16.9.5. Strategic Overview 16.10.BioMarin Pharmaceutical Inc. 16.10.1. Company Overview 16.10.2. Product Portfolio 16.10.3. SWOT Analysis 16.10.4. Financial Overview 16.10.5. Strategic Overview 16.11.MedPro Rx 16.11.1. Company Overview 16.11.2. Product Portfolio 16.11.3. SWOT Analysis 16.11.4. Financial Overview 16.11.5. Strategic Overview 16.12.Zymenex A/S 16.12.1. Company Overview 16.12.2. Product Portfolio 16.12.3. SWOT Analysis 16.12.4. Financial Overview 16.12.5. Strategic Overview 16.13.Merck Serono 16.13.1. Company Overview 16.13.2. Product Portfolio 16.13.3. SWOT Analysis 16.13.4. Financial Overview 16.13.5. Strategic Overview 17. Pre and Post COVID-19 Impact 17.1. Positive influence on the healthcare industry 17.2. The financial disruption of the manufacturing sector 17.3. Impact of COVID-19 on emerging companies 17.4. Significant mandates in the regulations initiated by healthcare administrations 17.5. The overall economic slowdown of the developing and developed nations 18. FutureWise SME Key Takeaway Points for Client
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders
2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study
3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights
4. Gaucher Disease Treatment Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances
5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Gaucher Disease Treatment Market Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework
6. Gaucher Disease Treatment Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies
7. Gaucher Disease Treatment Market, By Disease Type Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Type 1 (Neuropathic Forms) 7.2. Type 2 (Perinatal Lethal Form) 7.3. Type 3 (Slow-Neurologic Decay Form)
8. Gaucher Disease Treatment Market, By Medication Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Enzyme replacement therapy (ERT) 8.1.1. Imiglucerase (Cerezyme) 8.1.2. Velaglucerase alfa (VPRIV) 8.1.3. Taliglucerase alfa (Elelyso) 8.1.4. Others 8.2. Substrate reduction therapy (SRT) 8.2.1. Glucosylceramide synthase inhibitors 8.2.1.1. Miglustat 8.2.1.2. Eliglustat 8.3. Surgical 8.3.1. Bone marrow transplant 8.3.2. Spleen Removal
9. Gaucher Disease Treatment Market, By End User Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. Hospitals 9.2. Ambulatory Surgical Centers 9.3. Clinical research institutes
10. North America Gaucher Disease Treatment Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 10.1. Introduction 10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 10.2.1. U.S.A 10.2.2. Canada 10.2.3. Mexico 10.3. Market Size (USD Million) Forecast for North America 2022-2028
11. Latin America Gaucher Disease Treatment Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 11.2.1. Brazil 11.2.2. Venezuela 11.2.3. Argentina 11.2.4. Rest of Latin America 11.3. Market Size (USD Million) Forecast for Latin America 2022-2028
12. Europe Gaucher Disease Treatment Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. Germany 12.2.2. U.K 12.2.3. France 12.2.4. Italy 12.2.5. Spain 12.2.6. Russia 12.2.7. Poland 12.2.8. Rest of Europe 12.3. Market Size (USD Million) Forecast for Europe 2022-2028
13. Asia Pacific Gaucher Disease Treatment Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. Japan 13.2.2. China 13.2.3. India 13.2.4. Australia and New Zealand 13.2.5. ASEAN 13.2.6. Rest of Asia Pacific 13.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028
14. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 14.2.1. GCC 14.2.2. Israel 14.2.3. South Africa 14.2.4. Rest of MEA 14.3. Market Size (USD Million) Forecast for MEA 2022-2028
15. Market Share Analysis and Competitive Landscape 15.1. Global Landscape - Key Players, Revenue and Presence 15.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 15.3. Global Emerging Companies 15.4. North America - Market Share Analysis and Key Regional Players 15.5. Europe - Market Share Analysis and Key Regional Players 15.6. Asia Pacific - Market Share Analysis and Key Regional Players 15.7. Global Key Player - Growth Matrix
16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts) 16.1. Abbott 16.1.1. Company Overview 16.1.2. Product Portfolio 16.1.3. SWOT Analysis 16.1.4. Financial Overview 16.1.5. Strategic Overview 16.2. Aptalis Pharma 16.2.1. Company Overview 16.2.2. Product Portfolio 16.2.3. SWOT Analysis 16.2.4. Financial Overview 16.2.5. Strategic Overview 16.3. Genzyme Corporation 16.3.1. Company Overview 16.3.2. Product Portfolio 16.3.3. SWOT Analysis 16.3.4. Financial Overview 16.3.5. Strategic Overview 16.4. GlaxoSmithKline (GSK) 16.4.1. Company Overview 16.4.2. Product Portfolio 16.4.3. SWOT Analysis 16.4.4. Financial Overview 16.4.5. Strategic Overview 16.5. Pfizer Inc. 16.5.1. Company Overview 16.5.2. Product Portfolio 16.5.3. SWOT Analysis 16.5.4. Financial Overview 16.5.5. Strategic Overview 16.6. Shire Human Genetic Therapies, Inc. 16.6.1. Company Overview 16.6.2. Product Portfolio 16.6.3. SWOT Analysis 16.6.4. Financial Overview 16.6.5. Strategic Overview 16.7. Eli Lilly and Company 16.7.1. Company Overview 16.7.2. Product Portfolio 16.7.3. SWOT Analysis 16.7.4. Financial Overview 16.7.5. Strategic Overview 16.8. Enobia Pharma Inc. 16.8.1. Company Overview 16.8.2. Product Portfolio 16.8.3. SWOT Analysis 16.8.4. Financial Overview 16.8.5. Strategic Overview 16.9. Anthera Pharmaceuticals, Inc. 16.9.1. Company Overview 16.9.2. Product Portfolio 16.9.3. SWOT Analysis 16.9.4. Financial Overview 16.9.5. Strategic Overview 16.10.BioMarin Pharmaceutical Inc. 16.10.1. Company Overview 16.10.2. Product Portfolio 16.10.3. SWOT Analysis 16.10.4. Financial Overview 16.10.5. Strategic Overview 16.11.MedPro Rx 16.11.1. Company Overview 16.11.2. Product Portfolio 16.11.3. SWOT Analysis 16.11.4. Financial Overview 16.11.5. Strategic Overview 16.12.Zymenex A/S 16.12.1. Company Overview 16.12.2. Product Portfolio 16.12.3. SWOT Analysis 16.12.4. Financial Overview 16.12.5. Strategic Overview 16.13.Merck Serono 16.13.1. Company Overview 16.13.2. Product Portfolio 16.13.3. SWOT Analysis 16.13.4. Financial Overview 16.13.5. Strategic Overview
17. Pre and Post COVID-19 Impact 17.1. Positive influence on the healthcare industry 17.2. The financial disruption of the manufacturing sector 17.3. Impact of COVID-19 on emerging companies 17.4. Significant mandates in the regulations initiated by healthcare administrations 17.5. The overall economic slowdown of the developing and developed nations
18. FutureWise SME Key Takeaway Points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics